Drug Patents Expiring in 2041
1. Drug name - DAPZURA RT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173189 | BAXTER HLTHCARE CORP | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(18 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 500MG/VIAL | POWDER;INTRAVENOUS | Prescription |
2. Drug name - EPIDIOLEX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11160795 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(18 years from now) | |
Drugs and Companies using CANNABIDIOL ingredient
Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/ML | SOLUTION;ORAL | Prescription |
3. Drug name - EXPAREL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(18 years from now) | |
| US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(18 years from now) | |
Drugs and Companies using BUPIVACAINE ingredient
Treatment: Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
| Strength | Dosage | Availability |
|---|---|---|
| 133MG/10ML (13.3MG/ML) | INJECTABLE, LIPOSOMAL;INJECTION | Prescription |
| 266MG/20ML (13.3MG/ML) | INJECTABLE, LIPOSOMAL;INJECTION | Prescription |
4. Drug name - NORLIQVA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(18 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; norliqva is indicated for the symptomatic treatment of chronic stable angina; norliqva is indicated for the treatment of confirmed or suspected vasospastic angina
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/ML | SOLUTION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.